Is Intel Stock a Buy Ahead of Earnings?

Intel shares are up about 85% year to date, but the article argues the stock is priced for perfection ahead of April 23 first-quarter 2026 earnings. Management previously guided Q1 revenue to $11.7 billion-$12.7 billion and gross margin to about 34.5%, both pressured by supply constraints. Intel is also burning cash, with about $10.3 billion in foundry operating losses in fiscal 2025 and negative $1.5 billion trailing-12-month free cash flow, offset only partly by optimism around the Terafab AI chip partnership.

Analysis

The market is now treating INTC less like a cyclical semiconductor and more like a strategic national-capex platform, which is a dangerous regime shift for valuation discipline. The Terafab linkage likely improves sentiment around Intel’s manufacturing credibility, but the second-order effect is that expectations for flawless execution have moved far ahead of cash generation. That creates a fragile setup where any evidence of delayed node ramp, lower wafer starts, or customer qualification slippage can trigger multiple compression rather than a simple earnings miss.

The biggest underappreciated issue is capital intensity versus timing. Even if the foundry narrative is real, the equity is now implicitly funding several years of losses before meaningful operating leverage arrives, and that path is likely to remain dilution- or debt-sensitive if free cash flow stays negative. In the near term, supply constraints can mechanically suppress revenue and margins at exactly the moment the stock is priced for acceleration, so the next 1-2 quarters matter far more than the long-dated AI story.

Consensus seems to be underestimating how much of the recent move is positioning-driven rather than fundamental re-rating. If earnings confirm constrained supply or only incremental foundry progress, the stock could de-rate quickly because investors are paying for a compressed timeline to profitability that management has not yet demonstrated. The more interesting trade is not whether Intel eventually works, but whether the market has already discounted that outcome too aggressively.

On the beneficiary side, any forced share gains by Intel in AI foundry services could pressure smaller pure-play foundry names on narrative, but in practice the near-term winners are the equipment and materials vendors if Intel’s capex cycle extends. The losers are late-cycle buyers of INTC chasing the momentum breakout; they are effectively underwriting execution risk at a premium multiple with asymmetric downside into earnings.

Key Decisions for Investors

• Short INTC into the 4/23 earnings print or via a defined-risk put spread; thesis is multiple compression if guidance shows any lingering supply/margin pressure. Risk/reward is attractive because downside can be 15-25% on a modest disappointment, while upside is limited unless the company meaningfully raises near-term profitability targets.
• If maintaining a bearish view, structure an INTC May/June put spread rather than outright short equity; the stock’s momentum and headline sensitivity make gap risk high, but the probability-weighted payoff still favors downside if execution noise appears.
• Use any post-earnings selloff in INTC to reassess for a longer-dated 6-12 month tactical long only if management proves supply normalization and free cash flow inflection; until then, avoid paying peak sentiment multiple for a multi-year turnaround.
• Watch NVDA only as a relative-strength hedge: if INTC disappoints, capital may rotate back into the highest-quality AI semis. A long NVDA / short INTC pair is cleaner than a directional Intel long because it isolates execution quality versus turnaround optionality.
• For event-driven traders, consider a small TSLA long-call hedge around the Intel announcement window only if you believe Terafab linkage increases probability of broader AI infrastructure capex follow-through; otherwise TSLA exposure is too indirect to justify standalone positioning.